https://scholars.lib.ntu.edu.tw/handle/123456789/525670
Title: | Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents | Authors: | LI-MIN HUANG LUAN-YIN CHANG Tang H. Bock H.L. CHUN-YI LU Huang F.-Y. Lin T.-Y. Lee C.-Y. |
Issue Date: | 2005 | Publisher: | Elsevier USA | Journal Volume: | 37 | Journal Issue: | 6 | Start page/Pages: | 517 | Source: | Journal of Adolescent Health | Abstract: | Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix?, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix?. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix? may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine. ? 2005 Society for Adolescent Medicine. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-27944432479&doi=10.1016%2fj.jadohealth.2005.08.009&partnerID=40&md5=ed5190ed49567d39eab2ebf10547af6d https://scholars.lib.ntu.edu.tw/handle/123456789/525670 |
ISSN: | 1054-139X | DOI: | 10.1016/j.jadohealth.2005.08.009 | SDG/Keyword: | antigen; diphtheria pertussis tetanus vaccine; filamentous hemagglutinin; hemagglutinin; immunoglobulin G antibody; pertactin; pertussis toxin; tetanus toxoid; unclassified drug; adolescent; adult; antibody blood level; article; blood sampling; child; clinical trial; diphtheria; drug induced disease; drug response; edema; enzyme linked immunosorbent assay; fatigue; female; fever; gastrointestinal symptom; headache; human; human tissue; immunogenicity; male; normal human; pain; pertussis; priority journal; protein content; tetanus; vaccination [SDGs]SDG3 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.